July 2008 PBAC Outcomes - Deferrals
|
Drug and Form |
Drug and Type |
Listing Requested by Sponsor |
PBAC Outcome and Comment |
|---|---|---|---|
| Dasatinib, tablet, 20 mg, 50 mg, 70 mg, (Sprycel®) Bristol-Myers Squibb Pharmaceuticals Minor submission |
Chronic myeloid leukaemia (CML) Acute lymphoblastic leukaemia (ALL) |
To request the removal of the 140 mg/day dosage restriction for both CML and ALL. | Deferred, pending further information. |
| Sponsor’s comments: | The sponsor will continue to work with the PBAC to reach a satisfactory outcome. |
